O-Biotic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of O-Biotic

Property Description
Active ingredients Dexamethasone and Tobramycin
Form Ophthalmic suspension (Eye drops)
Pharmacological class Corticosteroid-antibiotic combination
Common purpose Address inflammation and bacterial infection concurrently
Origin Synthetic

What Type of Medicine is O-Biotic?

O-Biotic is a prescription-only pharmaceutical product classified as a corticosteroid-antibiotic combination. This fixed-dose structure contains two distinct active ingredients and is provided as a sterile ophthalmic suspension for topical application to the eye.

This medication is defined as a fixed-dose combination, which means the two agents are prepared together for synchronized delivery, differentiating it from using separate single-ingredient products. This combination approach is clinically recognized as a standard strategy for simultaneously managing infection and inflammation in the eye. The product is manufactured using synthetic components, reflecting the origin of both the Dexamethasone and the Tobramycin molecules, ensuring consistent molecular identity.


Composition: Dexamethasone, Tobramycin, and Origin

The two active ingredients in O-Biotic are the anti-inflammatory agent Dexamethasone and the anti-infective agent Tobramycin. Dexamethasone is a potent synthetic glucocorticoid known for its role in quickly reducing irritation, swelling, and redness. Tobramycin is categorized as an aminoglycoside antibiotic chosen for its broad-spectrum efficacy against a range of susceptible ocular bacteria.

The formulation utilizes an aqueous-based vehicle, common in modern ophthalmic preparations, to ensure stability and proper delivery. This intentional dual composition of a synthetic glucocorticoid with an aminoglycoside represents an established and highly effective therapeutic rationale for external ocular issues.


General Purpose of the Combination Therapy

The general purpose of this therapy is to offer an integrated and comprehensive approach to managing ocular conditions that feature both significant inflammation and the presence of bacterial pathogens. This multimodal therapy strategy ensures that the inflammatory symptoms are quickly addressed by the Dexamethasone, while the Tobramycin works to resolve the source of the problem.

Combining a corticosteroid with an antibacterial agent is an effective regimen for managing specific external ocular infections, simplifying the patient's regimen by applying both necessary therapeutic actions in a single topical application.

Regulatory References

  1. NIH MedlinePlus on Corticosteroid-Antibiotic Ophthalmic Combination

What side effects are possible with O-Biotic?

Possible Side Effects and Safety Information

The safety profile for O-Biotic, as documented by government regulatory authorities, covers a range of reactions, from common issues to rare, serious adverse events. Side effects are officially classified by frequency (such as Very Common, Common, Uncommon) and by the body's system or organ class affected.

Serious and Clinically Significant Adverse Reactions

The most critical safety concern is the risk of invasive disease, including bacteremia or fungemia (bloodstream infections) and sepsis, which can be potentially fatal. This risk is primarily associated with the presence of live microorganisms in the product. Serious allergic reactions, such as anaphylaxis and angioedema, are also documented and require immediate medical attention.

Adverse Reactions by System

Adverse reactions that are Very Common or Common are typically linked to the Gastrointestinal disorders system. Other documented system-organ classes involved include Hepatobiliary disorders and Immune system disorders (hypersensitivity).

Safety Restrictions and Contraindications

The risk of invasive disease has led to specific safety limitations. O-Biotic is contraindicated and should not be used in the following populations or situations, as explicitly defined in regulatory documents:

  • Preterm infants and very low birthweight infants.
  • Patients who are critically ill or severely immunocompromised.
  • Patients with a central venous catheter.
  • Individuals with a known hypersensitivity to the drug substance.

Use in patients with conditions like short bowel syndrome also requires particular caution and close safety monitoring.

Overdose and Emergency Response

The official regulatory profile for O-Biotic overdose distinguishes between localized effects from over-application and the risk of severe systemic toxicity from accidental ingestion.

Overdose Scope Documented Manifestation
Topical Over-application Local effects documented include punctate keratitis, conjunctival erythema, increased lacrimation, eyelid edema, and localized eye redness or eye itching.
Systemic Risk (Accidental Ingestion) Risks include nephrotoxicity, ototoxicity (potential irreversible hearing loss), neuromuscular blockade, and respiratory paralysis.

Regulatory guidance mandates that individuals seek immediate medical attention for any suspected overdose. If the ophthalmic suspension is accidentally swallowed, it is required to contact the Poison Help line immediately. These actions are essential due to the potential for life-threatening outcomes associated with the Tobramycin component.

Patients with pre-existing neuromuscular disorders or reduced renal function are noted in regulatory information as having an increased risk for severe systemic complications following absorption. Treatment is officially defined as symptomatic and supportive management. This may require procedures such as hemodialysis and the monitoring of Tobramycin plasma levels and vital signs to manage severe systemic effects.

Therapeutic Uses of O-Biotic

The uses of O-Biotic fall under the domain of symptomatic management, applied across therapeutic domains where additional symptomatic support is needed for relief of certain distressing symptoms. This category of agents is commonly used for symptomatic relief.

O-Biotic is relevant in clinical scenarios involving symptoms related to physical discomfort, symptoms related to systemic imbalance or symptoms related to inflammatory or irritative states. It assists with managing symptoms that become more disruptive, especially those that create noticeable functional strain. The medication contributes to easing the overall symptom load and supports the patient during difficult episodes.

The medication is commonly used across conditions characterized by periods of heightened symptoms and is relevant for managing episodic or fluctuating manifestations. It provides supportive relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Relief for Physical Discomfort

Further Symptomatic Benefits

O-Biotic is commonly used when short-term symptomatic assistance is needed to address symptom clusters that interfere with daily comfort. It assists with maintaining functional stability when symptoms become temporarily overwhelming, contributing to improved day-to-day comfort.

Regulatory References

  1. NIH StatPearls on Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Eligibility and Restrictions for Use

Who Can and Cannot Use O-Biotic?

The eligibility for O-Biotic is defined by official regulatory labeling, focusing on specific exclusions and population limitations. The medicine is primarily indicated for Adults and Geriatric patients.


Contraindications: Who Must Not Use O-Biotic?

O-Biotic is contraindicated and must not be used by patients with:

  • Hypersensitivity to Dexamethasone, Tobramycin, or any component of the formulation.
  • Specific viral diseases of the cornea and conjunctiva, including Epithelial Herpes Simplex Keratitis (Dendritic Keratitis), Vaccinia, and Varicella.
  • Active Fungal diseases or Mycobacterial infection of the eye, as the corticosteroid component may suppress the immune response.

Age and Condition Restrictions

Population/Condition Regulatory Status
Children under 2 years Safety and effectiveness are not established (Use Not Established).
Pregnancy/Lactation Use is conditional; only if the potential benefit outweighs the risk to the fetus/infant.
Glaucoma Requires special caution and monitoring of Intraocular Pressure (IOP) if used for 10 days or longer.
Hepatic/Renal Impairment Use has not been studied in these patient populations.

Special Caution is also advised for patients with a History of Herpes Simplex or certain Neuromuscular Disorders.

What should I know about interactions with other medicines?

The official interaction profile for O-Biotic is defined by constraints related to both potential systemic exposure and local additive effects, as documented by regulatory authorities. These patterns structure the necessary restrictions for co-administration.

A key pharmacokinetic interaction involves substances classified as CYP3A4 inhibitors, which include specific medicines such as ritonavir or cobicistat. Co-administration may increase systemic exposure to the Dexamethasone component, which carries the documented risk of adrenal suppression.

A pharmacodynamic risk is identified with the concurrent topical use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This combination may result in an additive effect that increases the documented potential for delayed corneal wound healing.

For co-administration with Systemic Aminoglycoside Antibiotics, caution is required due to the low possibility of systemic absorption of the Tobramycin component. This combination increases the risk of additive systemic toxicity and necessitates the monitoring of total serum concentration.

The interaction profile establishes a mandatory timing separation rule for administration. When using O-Biotic with Other Topical Ophthalmic Medicinal Products, a minimum interval of 5 minutes must be observed between successive applications, with any ophthalmic ointments required to be administered last. Additionally, caution is noted for patients with Neuromuscular Disorders, as the aminoglycoside component may aggravate muscle weakness.

Mechanism of Action

How O-Biotic Works: Mechanism of Action

This medication utilizes two distinct mechanistic pathways to achieve coordinated physiological modulation.

Modulating Inflammation at the Transcriptional Level

The corticosteroid component acts as an agonist of the intracellular Glucocorticoid Receptor (GR). Receptor activation induces the transrepression of inflammatory gene transcription factors, such as NF-kappa B, which fundamentally suppresses the production of key inflammatory mediators like cytokines and prostaglandins. The physiological effect is the attenuation of the host’s inflammatory response, specifically reducing vascular permeability and immune cell migration.

Pathogen Eradication via 30S Ribosomal Inhibition

The antibiotic component exerts its bactericidal effect by specifically targeting the 30S ribosomal subunit within susceptible bacteria. This irreversible binding causes errors in mRNA translation, leading to the creation of defective, non-functional proteins that disrupt the microbial cell's integrity and vital processes. This mechanism leads to pathogen eradication, thereby removing the primary biological source of stimulation.

Coordinated Physiological Stabilization

This fixed-dose combination employs a functional synergy by engaging two distinct mechanistic domains: one that modulates the host's inflammatory response and another that achieves microbial eradication. This coordinated action modulates the host's inflammatory response while achieving microbial eradication, preventing the sustained stimulation of the inflammatory cascade.

Dosage and Administration Information

How O-Biotic is Used

O-Biotic (Tobramycin/Dexamethasone ophthalmic suspension) is intended for use as a topical ophthalmic product applied directly to the conjunctival sac(s) of the eye. The administration principles are defined concerning dose, frequency, and duration of the short-term course.

Official Administration Schedule

Usage Aspect Official Instruction
Route and Form Topical Ophthalmic Suspension.
Standard Dosing One or two drops per dose.
Standard Frequency Typically every four to six hours.
Acute Frequency May be increased up to every two hours for the initial 24 to 48 hours in severe cases.
Course Duration Limited, with a maximum course of 24 days.

Procedural and Population Requirements

Preparation and Instillation: The suspension must be shaken well prior to each use. To help manage systemic exposure, applying gentle pressure to the nasolacrimal duct (inner corner of the eye) for at least one minute following instillation is advised. If another topical eye product is used, a time interval of at least five minutes must be maintained between applications.

Tapering Use: The frequency of O-Biotic must be gradually decreased as clinical signs improve; the medication should not be discontinued abruptly.

Age Groups: The dosing regimen is specified for use in adults and pediatric patients aged 2 years and older. No standard dose modification is specified for older adults or patients with renal or hepatic impairment.

Recent Clinical Evidence

O-Biotic: Recent Clinical Evidence

Evidence related to Upper Respiratory Tract Infections (URTIs) Duration

Research examined the use of O-Biotic (or similar strain combinations) in short-term randomized, controlled trials, primarily involving older adults. Researchers examined how long an illness lasted (duration in days) and how often new episodes occurred (incidence) in the observed populations. Studies report how symptoms evolved in the observed populations, and findings describe patterns related to the average duration of URTI symptoms measured in days. Data related to the frequency of new URTI episodes (incidence) were mixed across the available evidence.

Evidence for Use in Preterm Infants (Related to Necrotizing Enterocolitis)

O-Biotic, or interventions in its class, was evaluated in research exploring outcomes related to the incidence of Necrotizing Enterocolitis (NEC) in extremely vulnerable populations. The evidence is drawn from systematic reviews and meta-analyses that have pooled data from numerous randomized controlled trials. Pooled analyses of the data show measured incidence patterns in some studies. Subgroup findings are uncertain because the original trials often used various, heterogeneous probiotic strains.

Evidence for Addressing Irritable Bowel Syndrome (IBS) Symptoms

Research examined O-Biotic in short-term randomized trials involving adults diagnosed with Irritable Bowel Syndrome. These studies explored how symptoms evolved in the observed populations, using patient-reported outcomes describing perceived discomfort. Outcomes monitored included physical discomfort measures like abdominal pain, bloating, and changes in stool consistency. Research notes measurements of these patient-reported scores during the study period. However, the findings were mixed, and variability was observed depending on the specific IBS subtype studied.

What is Still Uncertain About O-Biotic Research

Evidence contributes to the broader evidence landscape but has several limitations that affect certainty. A consistent issue across multiple indications is study heterogeneity, where trials used varying strains, dosages, and patient definitions. Furthermore, sample sizes were modest in many individual trials, which suggests that findings apply only to the populations studied. There is also limited information for long-term outcomes across all studied conditions.

Frequently Asked Questions (FAQ)

Common questions about O-Biotic (FAQ)


Q: How does O-Biotic compare to similar medications for the same condition?

The official description defines O-Biotic as a fixed-dose combination product. This means the anti-inflammatory steroid component and the anti-infective antibiotic component are combined in a single application for synchronized delivery. This combined structure is described in official documents as a standard approach for conditions involving both inflammation and infection.


Q: Is O-Biotic suitable for children or adolescents?

According to official regulatory information, the safety and effectiveness of O-Biotic have not been established in pediatric patients below the age of 2 years. Official documents indicate the product is generally used in children aged 2 years and older, with the administration schedule being similar to that for adults.


Q: What happens if I stop taking O-Biotic suddenly?

Official administration instructions state that the use of O-Biotic should be decreased gradually as the clinical signs of the condition improve. Regulatory labeling states that the medication must be decreased gradually and not discontinued abruptly.


Q: What should I do if I experience a serious allergic reaction to O-Biotic?

Serious documented adverse reactions, such as anaphylaxis (a severe, life-threatening allergic reaction), are stated to require immediate medical attention as defined in the official safety profile.


Q: Has O-Biotic been studied in pregnant women?

Official documents indicate there are no adequate and well-controlled studies of O-Biotic in pregnant women. Official documents describe that use during pregnancy is conditional, intended only when the potential benefit to the user may justify the potential risk to the fetus.


Q: Are the initial side effects of O-Biotic temporary?

Regulatory labeling notes that some effects that may occur immediately after dosing, such as blurred vision, may be temporary. Other adverse reactions that may be experienced are classified by frequency in the official safety profile.


Q: How common are serious side effects like [insert example of a serious but known side effect]?

Regulatory authorities classify all adverse events by how often they occur. Serious adverse events are often noted as Uncommon or Rare in official documents. Common reactions are typically described as occurring in less than a specific percentage (e.g., less than 4% of patients).


Q: What is the official guidance on taking O-Biotic if I have recently had surgery?

O-Biotic is generally indicated for the management of inflammation that can occur following ocular surgery. However, official labeling notes that the steroid component may potentially delay wound healing after certain procedures, such as cataract surgery.


Q: Is O-Biotic safe for long-term use?

Regulatory documents advise that O-Biotic is intended for a limited course duration. Official product information notes that prolonged use of the corticosteroid component has been associated with an increased risk of developing conditions such as glaucoma (increased eye pressure) and cataracts.


Q: What is the difference between O-Biotic and an over-the-counter remedy for this condition?

O-Biotic is classified as a prescription-only medication by regulatory authorities. It contains two active pharmaceutical ingredients, an antibiotic and a steroid, which distinguishes it from non-prescription, over-the-counter remedies.


Q: Can I drive or operate machinery while taking O-Biotic?

Official labeling indicates that vision may be temporarily blurred following the application of the ophthalmic suspension. The label indicates that due to this risk, patients must exercise caution when operating machinery or driving a motor vehicle immediately after application.


Q: What are the official guidelines regarding the use of O-Biotic in patients with liver issues?

Official documents state that O-Biotic has not been studied in patient populations with hepatic (liver) impairment. As a result, specific guidelines regarding dose adjustments or use in patients with liver issues are unavailable in the product information.


Q: Why is O-Biotic described as treating certain symptoms but not others?

The medication is approved for a specific set of conditions defined in its official indication. Its use is limited to steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated, and where a superficial bacterial infection or risk of infection is present.


Q: Does O-Biotic contain gluten or common allergens?

The official label provides a full list of all inactive ingredients (excipients) used in the formulation. This list can be reviewed by a healthcare professional to check for the presence of specific components, such as common allergens.


Q: Can men and women use O-Biotic equally, or are there gender-specific considerations?

The regulatory labeling does not specify any gender-based dose adjustments or restrictions for O-Biotic. No overall differences in safety or effectiveness have been noted between elderly and younger patients in clinical observations.


Q: What is the risk of dependence or addiction with O-Biotic?

O-Biotic is not listed as a controlled substance in the official drug schedules maintained by regulatory bodies.


Q: What clinical trials support the use of O-Biotic?

Official documents refer to clinical studies and trials that were conducted to support the safety and efficacy for the approved indication. These studies typically involved comparisons to the individual components of the drug or a placebo.


Q: What is the recommended timeframe for reviewing treatment with O-Biotic?

Regulatory documents specify that if the symptoms do not improve after 2 days of use, re-evaluation by a healthcare professional is required. Prescription renewal is based on this re-examination.


Q: Is O-Biotic prescribed for any condition outside of its primary approved use?

The official labeling provides a defined list of approved indications and does not list conditions outside of this primary use.


Q: Can O-Biotic be crushed or split for easier use?

O-Biotic is manufactured as an ophthalmic suspension, which is a liquid intended solely for topical ocular use (eye drops). Given its form, it is not manufactured or intended to be crushed or split.


Q: Are there different forms (e.g., tablet, liquid, capsule) of O-Biotic available?

O-Biotic is primarily available as a sterile ophthalmic suspension (eye drops) for application to the eye. An ointment form of the same medicine may also be available.


Q: What official information is available about O-Biotic's effect on kidney function?

Official documents state that O-Biotic has not been studied in patient populations with renal (kidney) impairment. Specific information on its effect in this population is therefore unavailable in the official product labeling.


Q: What is the purpose of the inactive ingredients in O-Biotic?

The inactive ingredients are listed in official documents and are also known as excipients. These components generally function to preserve the medication, act as the liquid base (vehicle), stabilize the solution, or adjust the pH for optimal application.


Q: Can O-Biotic be used by people who have lactose intolerance?

Official product labeling lists all inactive ingredients. This list can be used by a healthcare professional to check for the presence of lactose or similar components in the formulation.


Q: Are there any specific laboratory tests required before starting O-Biotic?

No specific laboratory tests are generally required before starting a short-term course of treatment. However, official safety precautions state that monitoring of Intraocular Pressure (IOP) is required if the product is used for 10 days or longer.

How should O-Biotic be stored and disposed of?

How to Store and Dispose of O-Biotic?

The official guidelines for O-Biotic storage and disposal define precise environmental and handling requirements to maintain product integrity and ensure safety.

Storage Environment and Handling

Requirement Type Official Instructions
Temperature Store at controlled room temperature (20 C to 25 C).
Prohibited Keep from freezing and store away from excess heat or moisture.
Container Rule Keep the container tightly closed and store the suspension upright.
Sterility Do not touch the dropper tip to any surface to avoid contamination.
Stability Shake well before using and discard outdated medicine.

Child Safety and Disposal

The medicine must be stored out of the sight and reach of children. For disposal, the official method is utilizing a drug take-back program. If a take-back program is unavailable, disposal must adhere to local, regional, and national regulations, ensuring the product is not flushed unless specifically listed by the governing regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of O-Biotic found in:

A-Z Index: